Natera has announced a randomized, interventional study in melanoma that will use its Signaterd™ tumor-informed ctDNA assay — marketed as Signatera — to guide treatment decisions, moving the assay from prognostic monitoring into prospective trial design for a skin cancer where circulating tumor DNA status increasingly separates relapse risk after surgery.

The study is randomized, a design choice that matters. Retrospective and observational data have already linked post-surgical ctDNA positivity with poorer outcomes across multiple solid tumors, but interventional studies that assign therapy based on molecular results are the standard needed to change practice. By randomizing patients and intervening on the basis of Signatera results, Natera positions the assay as a decision tool rather than a passive marker.

Why does this matter for melanoma management?

For dermatologists and oncology teams managing resected melanoma, adjuvant therapy decisions still rest heavily on conventional staging — Breslow thickness, ulceration, nodal status, and AJCC stage. ctDNA offers a potential layer of dynamic, patient-specific risk information: a positive Signatera result after excision can indicate molecular residual disease before radiographic relapse, while clearance may support treatment de-escalation.

A randomized design can test both directions. Does acting on a positive signal improve outcomes? Can patients who clear ctDNA avoid unnecessary toxicity? Those are the questions interventional ctDNA trials are built to answer, and melanoma — with its well-characterized tumor mutational burden and established adjuvant immunotherapy and targeted-therapy options — is a logical disease setting for the approach.

What is Signatera?

Signatera is a tumor-informed, bespoke ctDNA assay. It is designed for the detection of molecular residual disease and recurrence monitoring in patients previously diagnosed with cancer. Each patient's assay is built from sequencing of the individual's tumor tissue to identify tumor-specific mutations, which are then tracked in blood plasma.

Natera has pursued a similar Signatera-guided interventional strategy in other tumor types. The melanoma announcement extends that program into cutaneous oncology, where earlier detection of residual disease after wide local excision and lymph node dissection could influence surveillance intervals, referral timing, and adjuvant treatment selection.

What comes next?

Enrollment, endpoints, and readout timing will determine whether the assay changes melanoma guidelines. For now, the announcement signals Natera's intent to generate the interventional evidence regulators and payers require before ctDNA-guided adjuvant decision-making becomes routine in resected melanoma care.